NCT06372613Recruiting
Association Between LRG and Histologic Remission in Ulcerative Colitis
What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed annually, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 15 Apr 2024
- Start date
- 25 Feb 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Showa Inan General Hospital
- Diseases
- Ulcerative colitis
- NCT number
- NCT06372613
What you commit to
- Study type: Observational
- Planned participants: 100
- From 25 Feb 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- definitive UC patients based on the standard criteria
Age in the registry: 20 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Showa Inan General Hospital Coordinator of this site? Confirm its status | Komagane | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.